Opendata, web and dolomites

Fucoderm

An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fucoderm project word cloud

Explore the words cloud of the Fucoderm project. It provides you a very rough idea of what is the project "Fucoderm" about.

generative    historically    meet    maintenance    marine    shortcomings    track    maximising    seaweed    brown    active    creams    commercial    4b    topical    itchy    opting    periods    formulation    collective    extracted    child    team    launch    discovery    attracting       cosmetic    comprise    company    healthcare    characterised    pharmaceutical    disease    convenience    steroid    pipeline    dominated    create    ad    reticent    expertise    biotechnology    responds    attributes    pharma    consumers    prescription    lesions    ingredient       steroids    inflammatory    immunomodulatory    90    turn    saccharides    sufferers    glycomar    toxicity    first    preferences    rashes    dilutive    grant    tend    moderate    skin    severe    drug    life    quality    eczema    dermatitis    atopic    fucoidan    record    2019    chronic    negative    fucoderm    treatment    market    reaching    glycobiology    mild    profitability    unpleasant    pursuit    cash    adults    treatments    extensive    created    nutraceutical    commercialisation    successful    natural   

Project "Fucoderm" data sheet

The following table provides information about the project.

Coordinator
GLYCOMAR LIMITED 

Organization address
address: DUNSTAFFNAGE MARINE LABOARATORY EUROPEAN CENTRE FOR MARINE BIOTECHNOLOGY DUNBEG ARGYLL
city: OBAN
postcode: PA37 1QA
website: www.glycomar.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.glycomar.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCOMAR LIMITED UK (OBAN) coordinator 50˙000.00

Map

 Project objective

Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers – reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) – are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomar’s eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed – a Fucoidan – Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomar’s extensive glycobiology expertise – the team has over 100 years’ collective experience in marine biotechnology and drug discovery/development – and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the €4b market, which is growing at 3,8% – maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUCODERM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUCODERM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More